Table 8.
Baseline characteristics before and after matching in the febuxostat and allopurinol groups between 2016 and 2018
| Classification | Before propensity score matching | After propensity score matching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Febuxostat (29,412 patients, 43.1%) | Allopurinol (38,905 patients, 57.0%) | STD (%) | Febuxostat (26,962 patients, 50.0%) | Allopurinol (26,962 patients, 50.0%) | STD (%) | ||||||
| N | (%) | N | (%) | N | (%) | N | (%) | ||||
| Sex | Men | 25,856 | 87.9 | 34,524 | 88.7 | − 2.6 | 24,067 | 89.3 | 24,302 | 90.1 | − 2.9 |
| Age | Mean (standard deviation) | 49.3 (± 17.0) | 48.1 (± 16.4) | 4.2 | 48.1 (± 16.4) | 47.6 (± 16.2) | 3.1 | ||||
|
Medication history |
Nonsteroidal anti-inflammatory drugs (NSAIDs) | 22,880 | 77.8 | 30,104 | 77.4 | 1.0 | 21,109 | 78.3 | 21,335 | 79.1 | − 2.0 |
| Systemic corticosteroids | 17,830 | 60.6 | 22,759 | 58.5 | 4.3 | 16,486 | 61.2 | 16,676 | 61.9 | − 1.4 | |
| Gout medication | 13,535 | 46.0 | 19,089 | 49.1 | − 6.1 | 13,020 | 48.3 | 13,288 | 49.3 | − 2.0 | |
| Anti-hyperlipidemic agents | 9152 | 31.1 | 9013 | 23.2 | 17.9 | 7488 | 27.8 | 7265 | 27.0 | 1.9 | |
| Hypoglycemic agents | 3650 | 12.4 | 3492 | 9.0 | 11.1 | 2722 | 10.1 | 2628 | 9.8 | 1.2 | |
| Hypotensors | 10,717 | 36.4 | 11,179 | 28.7 | 16.5 | 8,702 | 32.3 | 8504 | 31.5 | 1.6 | |
| CCI | Mean (standard deviation) | 1.3 (± 1.5) | 1.0 (± 1.3) | 21.4 | 1.1 (± 1.4) | 1.1 (± 1.3) | 0.0 | ||||
| 0 | 12,261 | 41.7 | 19,245 | 49.5 | − 15.7 | 12,254 | 45.5 | 12,655 | 46.9 | − 3.0 | |
| 1 | 6734 | 22.9 | 9660 | 24.8 | − 4.5 | 6707 | 24.9 | 6757 | 25.1 | − 0.4 | |
| 2 | 3577 | 12.2 | 4265 | 11.0 | 3.8 | 3270 | 12.1 | 3107 | 11.5 | 1.9 | |
| 3 | 2,076 | 7.1 | 2152 | 5.5 | 6.3 | 1697 | 6.3 | 1608 | 6.0 | 1.4 | |
| > 3 | 4764 | 16.2 | 3583 | 9.2 | 21.1 | 3034 | 11.3 | 2835 | 10.5 | 2.4 | |
| Disease history | Renal failure | 3912 | 13.3 | 1571 | 4.0 | 33.4 | 1585 | 5.9 | 1570 | 5.8 | 0.2 |
| Kidney stone | 302 | 1.0 | 312 | 0.8 | 2.4 | 229 | 0.9 | 229 | 0.9 | 0.0 | |
| Angina | 2689 | 9.1 | 2563 | 6.6 | 9.5 | 2006 | 7.4 | 1921 | 7.1 | 1.2 | |
| Diabetes mellitus | 6623 | 22.5 | 6375 | 16.4 | 15.5 | 5162 | 19.2 | 4983 | 18.5 | 1.7 | |
| Peripheral arterial disease | 22 | 0.1 | 14 | 0.0 | 1.6 | 19 | 0.1 | 12 | 0.0 | 1.1 | |
| Degenerative arthritis | 3431 | 11.7 | 3675 | 9.5 | 7.2 | 3,123 | 11.6 | 3066 | 11.4 | 0.7 | |
| Hypertension | 12,641 | 43.0 | 13,232 | 34.0 | 18.5 | 10,349 | 38.4 | 10,087 | 37.4 | 2.0 | |
| Hyperlipidemia | 13,095 | 44.5 | 13,547 | 34.8 | 19.9 | 11,081 | 41.1 | 10,830 | 40.2 | 1.9 | |
| Obesity | 56 | 0.2 | 53 | 0.1 | 1.3 | 54 | 0.2 | 39 | 0.1 | 1.3 | |
| Smoking | 29 | 0.1 | 34 | 0.1 | 0.4 | 22 | 0.1 | 23 | 0.1 | − 0.1 | |
| History of cardiovascular disease | Myocardial infarction | 438 | 1.5 | 416 | 1.1 | 3.7 | 327 | 1.2 | 304 | 1.1 | 0.8 |
| Ischemic heart disease | 1377 | 4.7 | 1287 | 3.3 | 7.0 | 1001 | 3.7 | 966 | 3.6 | 0.7 | |
| Stroke | 1668 | 5.7 | 1694 | 4.4 | 6.0 | 1266 | 4.7 | 1186 | 4.4 | 1.4 | |
| Transient ischemic attack | 332 | 1.1 | 386 | 1.0 | 1.3 | 264 | 1.0 | 263 | 1.0 | 0.0 | |
| Heart failure | 2268 | 7.7 | 1819 | 4.7 | 12.6 | 1,589 | 5.9 | 1,509 | 5.6 | 1.3 | |
| Coronary revascularization | 594 | 2.0 | 538 | 1.4 | 4.9 | 438 | 1.6 | 392 | 1.5 | 1.4 | |
Medication history, CCI, disease history: results of use or diagnosis for 1 year prior to the index date
If the absolute value of the standardized difference (STD) was higher than 10, it was judged to be different between the two groups
Propensity score matching: propensity scores of the febuxostat and allopurinol groups were matched 1:1 with a caliper width of 0.005
Average follow-up of 305 days in the febuxostat and allopurinol groups between 2016 and 2018